Lord Abbett & CO. LLC Sells 105,239 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Lord Abbett & CO. LLC cut its position in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 12.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 713,258 shares of the life sciences company's stock after selling 105,239 shares during the period. Lord Abbett & CO. LLC owned 0.92% of Integra LifeSciences worth $12,960,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. Blue Trust Inc. boosted its holdings in shares of Integra LifeSciences by 100.5% in the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company's stock worth $26,000 after acquiring an additional 444 shares in the last quarter. CWM LLC boosted its stake in Integra LifeSciences by 50.8% in the second quarter. CWM LLC now owns 1,262 shares of the life sciences company's stock worth $37,000 after purchasing an additional 425 shares in the last quarter. KBC Group NV grew its holdings in shares of Integra LifeSciences by 65.2% during the third quarter. KBC Group NV now owns 2,839 shares of the life sciences company's stock worth $52,000 after purchasing an additional 1,120 shares during the last quarter. Northwest Investment Counselors LLC acquired a new stake in shares of Integra LifeSciences in the third quarter valued at $73,000. Finally, Canada Pension Plan Investment Board bought a new position in shares of Integra LifeSciences in the second quarter valued at about $114,000. 84.78% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on IART. Citigroup increased their price objective on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a "sell" rating in a report on Tuesday, November 5th. Bank of America decreased their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating on the stock in a research note on Monday, October 7th. Truist Financial dropped their price objective on shares of Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating for the company in a research report on Monday, October 14th. Morgan Stanley began coverage on Integra LifeSciences in a research report on Monday, December 2nd. They issued an "underweight" rating and a $20.00 price objective on the stock. Finally, BTIG Research upgraded Integra LifeSciences from a "sell" rating to a "neutral" rating in a research report on Monday, October 7th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $23.00.

Integra LifeSciences Trading Down 1.3 %

Shares of IART stock traded down $0.32 during trading hours on Monday, reaching $23.71. The company had a trading volume of 544,807 shares, compared to its average volume of 1,062,534. Integra LifeSciences Holdings Co. has a 1-year low of $16.81 and a 1-year high of $45.42. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of -263.44, a P/E/G ratio of 0.82 and a beta of 1.15. The company has a 50 day moving average of $22.24 and a 200 day moving average of $23.64.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.02. The firm had revenue of $380.80 million for the quarter, compared to analyst estimates of $375.81 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company's quarterly revenue was down .4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.76 earnings per share. On average, equities research analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Insider Buying and Selling at Integra LifeSciences

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the transaction, the executive vice president now directly owns 56,182 shares in the company, valued at approximately $1,357,357.12. The trade was a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 3.10% of the company's stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.